Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
High Grade Ovarian Serous Adenocarcinoma: early-phase trial registry
2 of 7 indexed High Grade Ovarian Serous Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 2 currently recruiting · #2,497 of 28,707 conditions by registered trial count
High Grade Ovarian Serous Adenocarcinoma: 7 US clinical trials tracked, 2 recruiting.
High Grade Ovarian Serous Adenocarcinoma is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition high-grade-ovarian-serous-adenocarcinoma
OPEN 2 | RECR 29% | LATE 0 | EARLY 6 | RANK #2497 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acromegaly (29% recruiting · 14 trials)
High Grade Ovarian Serous Adenocarcinoma lists 2 open slots (29% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for High Grade Ovarian Serous Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
High Grade Ovarian Serous Adenocarcinoma is recruiting below its size-band peers.
2 of 7 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates High Grade Ovarian Serous Adenocarcinoma research.
M.D. Anderson Cancer Center accounts for 5 of 7 trials (71.4%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most High Grade Ovarian Serous Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 31 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
High Grade Ovarian Serous Adenocarcinoma research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Massachusetts General Hospital
NCT04794322
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Zumutor Biologics
NCT06451497
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
NCT02208375
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
NCT03586661
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
M.D. Anderson Cancer Center
NCT05114421
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
M.D. Anderson Cancer Center
NCT03943173
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
NCT02316834
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on High Grade Ovarian Serous Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on High Grade Ovarian Serous Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this High Grade Ovarian Serous Adenocarcinoma page
7 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 High Grade Ovarian Serous Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most High Grade Ovarian Serous Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This High Grade Ovarian Serous Adenocarcinoma condition card totals 7 registered trials; most-linked intervention Olaparib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.